Abstract

PurposeTo evaluate the performance of combined PET and multiparametric MRI (mpMRI) radiomics for the group-wise prediction of postsurgical Gleason scores (psGSs) in primary prostate cancer (PCa) patients.MethodsPatients with PCa, who underwent [68 Ga]Ga-PSMA-11 PET/MRI followed by radical prostatectomy, were included in this retrospective analysis (n = 101). Patients were grouped by psGS in three categories: ISUP grades 1–3, ISUP grade 4, and ISUP grade 5. mpMRI images included T1-weighted, T2-weighted, and apparent diffusion coefficient (ADC) map. Whole-prostate segmentations were performed on each modality, and image biomarker standardization initiative (IBSI)-compliant radiomic features were extracted. Nine support vector machine (SVM) models were trained: four single-modality radiomic models (PET, T1w, T2w, ADC); three PET + MRI double-modality models (PET + T1w, PET + T2w, PET + ADC), and two baseline models (one with patient data, one image-based) for comparison. A sixfold stratified cross-validation was performed, and balanced accuracies (bAcc) of the predictions of the best-performing models were reported and compared through Student’s t-tests. The predictions of the best-performing model were compared against biopsy GS (bGS).ResultsAll radiomic models outperformed the baseline models. The best-performing (mean ± stdv [%]) single-modality model was the ADC model (76 ± 6%), although not significantly better (p > 0.05) than other single-modality models (T1w: 72 ± 3%, T2w: 73 ± 2%; PET: 75 ± 5%). The overall best-performing model combined PET + ADC radiomics (82 ± 5%). It significantly outperformed most other double-modality (PET + T1w: 74 ± 5%, p = 0.026; PET + T2w: 71 ± 4%, p = 0.003) and single-modality models (PET: p = 0.042; T1w: p = 0.002; T2w: p = 0.003), except the ADC-only model (p = 0.138). In this initial cohort, the PET + ADC model outperformed bGS overall (82.5% vs 72.4%) in the prediction of psGS.ConclusionAll single- and double-modality models outperformed the baseline models, showing their potential in the prediction of GS, even with an unbalanced cohort. The best-performing model included PET + ADC radiomics, suggesting a complementary value of PSMA-PET and ADC radiomics.

Highlights

  • Prostate cancer (PCa) is a leading cause of cancer-associated morbidity and mortality in men [1]

  • We investigated the performance of handcrafted radiomic features extracted from pre-therapeutic ­[68 Ga]Ga-PSMA-11 Positron emission tomography (PET)/MRI in predicting postsurgical Gleason scores (psGSs) in three categories (GGG 1–3, Gleason Grade Groups (GGG) 4, GGG 5)

  • From the 71 patients with both available psGS and biopsy Gleason score (GS) (bGS) (GGG 1–3: 62% (n = 44); GGG 4: 20% (n = 14); GGG 5: 18% (n = 13)), our model outperformed the bGS in predicting psGS overall pvalue paƟent baseline radiomics baseline T1-weighted image (T1w) T2-weighted image (T2w) apparent diffusion coefficient (ADC) PET PET+T1w PET+T2w

Read more

Summary

Introduction

Prostate cancer (PCa) is a leading cause of cancer-associated morbidity and mortality in men [1]. Positron emission tomography (PET) imaging with PCa-specific tracers can help the delineation of suspicious lesions for guiding repeated biopsies or to improve the sensitivity of lesion detection [2, 4]. 68 Ga-radiolabelled prostate-specific membrane antigen PET (PSMA-PET) demonstrated superiority over other imaging modalities and PET radiotracers in localizing primary staging and biochemical recurrent PCa [5,6,7]. Patients with histologically confirmed PCa are initially stratified into risk groups according to serum prostate-specific antigen (PSA) levels, histological findings, and digital-rectal examination results [4]. The Gleason score (GS) extracted from biopsy results or after radical prostatectomy (RP) is the main tool for prognosis, and an indicator of the aggressiveness of PCa. Recently, the International Society of Urological Pathology (ISUP) reached a consensus regrouping of the GS into 5 Gleason Grade Groups (GGG) [11], according to their correlation with patient outcome

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.